Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma

PLoS Medicine

Volumn 5, Issue 1, 2008, Pages 0139-0151

  Cloughesy, Tim F ^a   Yoshimoto, Koji ^a,f   Nghiemphu, Phioanh ^a   Brown, Kevin ^b   Dang, Julie ^a   Zhu, Shaojun ^a   Hsueh, Teli ^a   Chen, Yinan ^a   Wang, Wei ^c   Youngkin, David ^b   Liau, Linda ^a   Martin, Neil ^a   Becker, Don ^a   Bergsneider, Marvin ^a   Lai, Albert ^a   Green, Richard ^d   Oglesby, Tom ^c   Koleto, Michael ^c   Trent, Jeff ^b   Horvath, Steve ^a   Mischel, Paul S ^a   Mellinghoff, Ingo K ^a   Sawyers, Charles L ^e   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c Taylor Technology Inc   (United States)

^d Kaiser Permanente ^*  (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN S6; RAPAMYCIN; ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG INHIBITION; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPOKALEMIA; MALE; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL; ADJUVANT THERAPY; BRAIN TUMOR; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEEDBACK SYSTEM; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; SALVAGE THERAPY; SIGNAL TRANSDUCTION; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL DIVISION; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; FEEDBACK, PHYSIOLOGICAL; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM PROTEINS; NEOPLASM RECURRENCE, LOCAL; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RIBOSOMAL PROTEIN S6; SALVAGE THERAPY; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 38849208347     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0050008     Document Type: Article

References (52)

1. Arteaga CL, Baselga J (2004) Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Cancer Cell 5: 525-531.
2. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96: 213-268.
3. Michaelis LC, Ratain MJ (2006) Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 6: 409-414.
4. Smith IE, Walsh G, Skene A, Llombart A, Mayordomo JI, et al. (2007) A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol 25: 3816-3822.
5. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, et al. (2007) Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99: 167-170.
6. Bjornsti MA, Houghton PJ (2004) The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335-348.
7. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281.
8. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
9. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, et al. (2001) Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/ mTOR. Proc Natl Acad Sci U S A 98: 10314-10319.
10. Podsypanina K, Lee RT, Politis C, Hennessy I, Crane A, et al. (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98: 10320-10325.
11. Yu K, Toral-Barza L, Discafani C, Zhang WG, Skotnicki J, et al. (2001) mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8: 249-258.
12. Shi Y, Gera J, Hu L, Hsu JH, Bookstein R, et al. (2002) Enhanced sensitivity of multiple myeloma cells containing PTEN mutations to CCI-779. Cancer Res 62: 5027-5034.
13. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, et al. (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601.
14. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, et al. (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337.
15. Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, et al. (2006) Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475-482.
16. Quinn JA, Desjardins A, Weingart J, Brem H, Dolan ME, et al. (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23: 7178-7187.
17. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, et al. (2003) Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746.
18. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, et al. (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012-2024.
19. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
20. Pende M, Um SH, Mieulet V, Sticker M, Goss VL, et al. (2004) S6K1(-/-)/ S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24: 3112-3124.
21. Roux PP, Shahbazian D, Vu H, Holz MK, Cohen MS, et al. (2007) RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 282: 14056-14064.
22. Yatscoff R, LeGatt D, Keenan R, Chackowsky P (1993) Blood distribution of rapamycin. Transplantation 56: 1202-1206.
23. Sun XJ, Goldberg JL, Qiao LY, Mitchell JJ (1999) Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteasome degradation pathway. Diabetes 48: 1359-1364.
24. Haruta T, Uno T, Kawahara J, Takano A, Egawa K, et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783-794.
25. Tremblay F, Marette A (2001) Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. J Biol Chem 276: 38052-38060.
26. Takano A, Usui I, Haruta T, Kawahara J, Uno T, et al. (2001) Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Mol Cell Biol 21: 5050-5062.
27. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, et al. (2005) Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res 65: 7052-7058.
28. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
29. Kovacina KS, Park GY, Bae SS, Guzzetta AW, Schaefer E, et al. (2003) Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem 278: 10189-10194.
30. Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH (2007) Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol 9: 316-323.
31. Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, et al. (2007) PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell 25: 903-915.
32. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
33. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
34. Ichimura K, Ohgaki H, Kleihues P, Collins VP (2004) Molecular pathogenesis of astrocytic tumours. J Neurooncol 70: 137-160.
35. Cui X, Kim HJ, Kuiatse I, Kim H, Brown PH, et al. (2006) Epidermal growth factor induces insulin receptor substrate-2 in breast cancer cells via c-Jun NH(2)-terminal kinase/activator protein-1 signaling to regulate cell migration. Cancer Res 66: 5304-5313.
36. Zhang H, Bajraszewski N, Wu E, Wang H, Moseman AP, et al. (2007) PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest 117: 730-738.
37. Parsons R (2004) Human cancer, PTEN and the PI-3 kinase pathway. Semin Cell Dev Biol 15: 171-176.
38. Sawyers CL (2003) Will mTOR inhibitors make it as cancer drugs? Cancer Cell 4: 343-348.
39. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, et al. (2005) Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23: 5294-5304.
40. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, et al. (2004) Phase I/ pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs 22: 427-435.
41. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, et al. (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361.
42. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9-22.
43. Sawyers CL (2005) Making progress through molecular attacks on cancer. Cold Spring Harb Symp Quant Biol 70: 479-482.
44. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, Dowell JM, Reardon DA, et al. (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: 1253-1259.
45. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, et al. (2005) Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med 46: 114-120.
46. Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, et al. (2003) Loss of PTEN/ MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812-2822.
47. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, et al. (2006) Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864-7869.
48. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, et al. (2007) Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell 12: 81-93.
49. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, et al. (2006) A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341-349.
50. Faivre S, Kroemer G, Raymond E (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671-688.
51. Thomas GV, Tran C, Mellinghoff IK, Welsbie DS, Chan E, et al. (2006) Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12: 122-127.
52. Kummar S, Kinders R, Rubinstein L, Parchment RE, Murgo AJ, et al. (2007) Compressing drug development timelines in oncology using phase '0' trials. Nat Rev Cancer 7: 131-139